News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2012

Epigenomics AG submits the third module in its PMA filing with FDA for Epi proColon®

12.06.2012 | Press_release_Epigenomics_AG_Third_PMA_Module Berlin, Germany, and Seattle, WA, U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, announced today that it has submitted the third module of its Premarket Approval (PMA) application to the United States Food & Drug Administration (FDA) for its blood-based colorectal cancer screening test Epi proColon®.

Read more

Epigenomics AG Announces Q1 2012 Financial Results and Operational Highlights

09.05.2012 | 20120509_Press_release_Epigenomics_Q1_results_ddw Berlin, Germany, and Seattle, WA, U.S.A., May 9, 2012 – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, announced today its financial results for the first quarter ending March 31, 2012.

Read more

Epigenomics AG Enrolls First Participant in its FIT comparative study with Epi proColon®

11.04.2012 | 120411_Epigenomics_Press_release_fit_first_patient Berlin, Germany, and Seattle, WA, U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today announced the start of the head-to-head comparative study of Epi proColon® with fecal immunochemical testing (FIT) for colorectal cancer detection. Meanwhile the first study subject has been enrolled.

Read more

Epigenomics AG: Full Year Results for the Year Ended 31 December 2011

23.03.2012 | 120323_Epigenomics_press_release_FY_Results Development of second generation product completed, PMA filing process initiated in the US Over 26,000 Septin9 laboratory-developed tests sold by North American partners in 2011 Tight fiscal control after implemented restructuring in 2011 Berlin, Germany, and Seattle, WA, U.S.A., March 23, 2012 – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular […]

Read more

Epigenomics AG Plans Changes in the Composition and Size of its Supervisory Board

16.03.2012 | 120316_Epigenomics_AG_Press_release_Supervisory_Board Berlin, Germany and Seattle, WA, U.S.A., March 16, 2012 – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, announced today that it was decided to propose to the shareholders of the company at its upcoming Annual General Meeting (AGM) on May 2, 2012 to vote in favor of […]

Read more

Ad hoc: Epigenomics AG Plans Changes in the Composition and Size of its Supervisory Board

PDF 158 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516) today decided to propose to the shareholders of the company at the upcoming Annual General Meeting on May 2, 2012 to vote in favor of a reduction of the size of the Supervisory Board from currently six to three members. Furthermore, the company’s Chairman, […]

Read more